Columbus Circle Investors’s Sage Therapeutics SAGE Stock Holding History

Columbus Circle Investors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-91,847	Closed	-$6.63M	–	165
2019 Q4	$6.63M	Sell	91,847 -4,282	-4%	-$527K	0.29%	111
2019 Q3	$13.5M	Sell	96,129 -4,091	-4%	-$684K	0.5%	79
2019 Q2	$18.3M	Buy	100,220 +14,217	+17%	+$2.43M	0.49%	70
2019 Q1	$13.7M	Sell	86,003 -15,487	-15%	-$2.24M	0.35%	84
2018 Q4	$9.72M	Buy	101,490 +8,559	+9%	+$980K	0.28%	100
2018 Q3	$13.1M	Sell	92,931 -565	-0.6%	-$87.2K	0.26%	123
2018 Q2	$14.6M	Buy	93,496 +65,211	+231%	+$10.2M	0.3%	116
2018 Q1	$4.56M	Buy	28,285 +7,063	+33%	+$1.2M	0.09%	166
2017 Q4	$3.5M	Buy	+21,222	New	+$2.06M	0.07%	164
2016 Q3	–	Sell	-36,005	Closed	-$1.08M	–	297
2016 Q2	$1.08M	Buy	+36,005	New	+$1.2M	0.01%	229

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Columbus Circle Investors's SAGE Position: Q1 2020 in Review

Columbus Circle Investors sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 91,847 shares — an estimated $6.63M sold.

Columbus Circle Investors first reported a position in SAGE in Q2 2016 and held it in 10 quarters. The position peaked at $18.3M in Q2 2019. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

Columbus Circle Investors reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
Columbus Circle Investors sold 91,847 Sage Therapeutics shares in Q1 2020, an estimated $6.63M.
Columbus Circle Investors first reported a position in Sage Therapeutics in Q2 2016 and held it in 10 quarters.
Columbus Circle Investors's Sage Therapeutics position peaked at $18.3M in Q2 2019.
230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Columbus Circle Investors's 13F filing for Q1 2020, filed 28 Apr 2020.